Beljkas, M.; Petkovic, M.; Vuletic, A.; Djuric, A.; Santibanez, J.F.; Srdic-Rajic, T.; Nikolic, K.; Oljacic, S.
Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design. Pharmaceutics 2024, 16, 1250.
https://doi.org/10.3390/pharmaceutics16101250
AMA Style
Beljkas M, Petkovic M, Vuletic A, Djuric A, Santibanez JF, Srdic-Rajic T, Nikolic K, Oljacic S.
Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design. Pharmaceutics. 2024; 16(10):1250.
https://doi.org/10.3390/pharmaceutics16101250
Chicago/Turabian Style
Beljkas, Milan, Milos Petkovic, Ana Vuletic, Ana Djuric, Juan Francisco Santibanez, Tatjana Srdic-Rajic, Katarina Nikolic, and Slavica Oljacic.
2024. "Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design" Pharmaceutics 16, no. 10: 1250.
https://doi.org/10.3390/pharmaceutics16101250
APA Style
Beljkas, M., Petkovic, M., Vuletic, A., Djuric, A., Santibanez, J. F., Srdic-Rajic, T., Nikolic, K., & Oljacic, S.
(2024). Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design. Pharmaceutics, 16(10), 1250.
https://doi.org/10.3390/pharmaceutics16101250